首页> 外文期刊>JAMA: the Journal of the American Medical Association >Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics (see comments)
【24h】

Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics (see comments)

机译:Medicare人群中颈动脉内膜切除术死亡率的变化:试验医院,数量和患者特征(请参阅评论)

获取原文
获取原文并翻译 | 示例
       

摘要

CONTEXT: The North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the Asymptomatic Carotid Atherosclerosis Study (ACAS) demonstrated the efficacy of carotid endarterectomy (CEA) in reducing the risk of stroke and death in selected patients when surgery was performed in institutions whose participation depended on demonstrated excellence. Thirty-day mortality rates in the trials were very low: 0.6% in NASCET and 0.1% in ACAS. OBJECTIVE: To assess perioperative mortality among Medicare patients undergoing CEA in all nonfederal institutional settings. DESIGN: Retrospective national cohort study. SETTING AND PATIENTS: All 113300 Medicare patients undergoing CEA during 1992 and 1993 in "trial hospitals" (those participating in NASCET and ACAS, n=86) and "nontrial hospitals" (all other nonfederal institutions performing CEAs, n=2613). Nontrial hospitals were stratified into terciles based on volume of CEAs performed. MAIN OUTCOME MEASURES: Crude and adjusted perioperative (30 day) mortality rates. RESULTS: The perioperative mortality rate was 1.4% (95% confidence interval [CI], 1.2%-1.7%) at trial hospitals; mortality in nontrial hospitals was higher: 1.7% (95% CI, 1.6%-1.8%) (high volume); 1.9% (95% CI, 1.7%-2.1 %) (average volume); 2.5% (95% CI, 2.0%-2.9%) (low volume); (P for trend, <.001). In multivariate modeling, patients undergoing their procedures at trial hospitals had a mortality risk reduction of 15% (95% CI, 0%-31%) compared with high-volume nontrial hospitals, 25% (95% CI, 7%-40%) compared with average-volume hospitals, and 43% (95% CI, 25%-56%) compared with low-volume hospitals (P for trend, <.001). CONCLUSION: Medicare patients' perioperative mortality following CEA is substantially higher than that reported in the trials, even in those institutions that participated in the randomized studies. Caution is advised in translating the efficacy of carefully controlled studies of CEA to effectiveness in everyday practice.
机译:背景:北美有症状颈动脉内膜切除术试验(NASCET)和无症状颈动脉粥样硬化研究(ACAS)证明,在参与程度较高的机构中进行手术时,颈动脉内膜切除术(CEA)可以有效降低选定患者的中风和死亡风险。表现出卓越。试验的30天死亡率非常低:NASCET为0.6%,ACAS为0.1%。目的:评估所有非联邦机构环境中接受CEA的Medicare患者的围手术期死亡率。设计:回顾性全国队列研究。地点和患者:在1992年至1993年期间,在“试验医院”(参加NASCET和ACAS的患者,n = 86)和“非试验医院”(所有其他进行CEA的非联邦机构,n = 2613)中接受CEA的113300名Medicare患者。根据执行的CEA数量,将非试验医院分为三级。主要观察指标:粗略和调整后的围手术期(30天)死亡率。结果:试验医院的围手术期死亡率为1.4%(95%置信区间[CI],1.2%-1.7%);非试验医院的死亡率较高:1.7%(95%CI,1.6%-1.8%)(高容量); 1.9%(95%CI,1.7%-2.1%)(平均体积); 2.5%(95%CI,2.0%-2.9%)(低音量); (P表示趋势,<。001)。在多变量建模中,在试验医院接受手术的患者的死亡率风险降低了15%(95%CI,0%-31%),而在大型非试验医院中,死亡率降低了25%(95%CI,7%-40%) )与平均数量的医院相比,有43%(95%CI,25%-56%)与小数量的医院相比(趋势P,<。001)。结论:CEA后的Medicare患者围手术期死亡率大大高于试验中报道的死亡率,即使在参加随机研究的机构中也是如此。建议谨慎地将CEA对照研究的功效转化为日常实践的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号